Investor Relations :: Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

View all news

Latest News

Jul 22, 2024

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

May 15, 2024

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Feb 13, 2024

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

View all news

Q3 2024

Quarter Ended Mar 31, 2024

Earnings Release

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2023

2022 Proxy Statement

Leadership

View Management Team View Board of Directors

IR Contacts

Company

Anebulo Pharmaceuticals, Inc.
1017 Ranch Road 620 South
Suite 107
Lakeway, TX 78734
T: 512-598-0931
ir@anebulo.com

Investor Relations

Adanna G. Alexander, PhD
T: (646) 942-5603
Adanna@RussoPR.com

Madison Damour
madison@anebulo.com

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
8th Floor
New York, NY 10004

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.